These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 18387078

  • 21. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.
    Sreenan S, Virkamäki A, Zhang K, Hansen JB, PREDICTIVE study group.
    Int J Clin Pract; 2008 Dec; 62(12):1971-80. PubMed ID: 19166444
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.
    Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E, Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group.
    Diabetes Care; 2004 May; 27(5):1081-7. PubMed ID: 15111525
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB.
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [Abstract] [Full Text] [Related]

  • 27. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Honka M, Ackermann RW, Meriläinen M, Gallwitz B, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2008 Feb; 24(2):369-76. PubMed ID: 18096110
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A, Schweitzer MA, Häring HU, 4001 Study Group.
    Ann Intern Med; 2003 Jun 17; 138(12):952-9. PubMed ID: 12809451
    [Abstract] [Full Text] [Related]

  • 30. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.
    Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober S.
    Diabet Med; 2010 Feb 17; 27(2):181-8. PubMed ID: 20546262
    [Abstract] [Full Text] [Related]

  • 31. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G.
    Diabetologia; 2008 Mar 17; 51(3):408-16. PubMed ID: 18204830
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes.
    Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B.
    Clin Ther; 2006 Oct 17; 28(10):1569-81. PubMed ID: 17157113
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes.
    Smeeton F, Shojaee Moradie F, Jones RH, Westergaard L, Haahr H, Umpleby AM, Russell-Jones DL.
    Diabetologia; 2009 Nov 17; 52(11):2317-23. PubMed ID: 19707744
    [Abstract] [Full Text] [Related]

  • 36. Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.
    Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V.
    Pediatr Diabetes; 2011 Nov 17; 12(7):632-41. PubMed ID: 21418455
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
    Davies MJ, Gross JL, Ono Y, Sasaki T, Bantwal G, Gall MA, Niemeyer M, Seino H, BEGIN BB T1 Study Group.
    Diabetes Obes Metab; 2014 Oct 17; 16(10):922-30. PubMed ID: 24702700
    [Abstract] [Full Text] [Related]

  • 38. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis.
    Szypowska A, Golicki D, Groele L, Pańkowska E.
    Pol Arch Med Wewn; 2011 Oct 17; 121(7-8):237-46. PubMed ID: 21878861
    [Abstract] [Full Text] [Related]

  • 39. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
    Fakhoury W, Lockhart I, Kotchie RW, Aagren M, LeReun C.
    Pharmacology; 2008 Oct 17; 82(2):156-63. PubMed ID: 18679040
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.